Q3 Earnings Estimate for Novavax Issued By Zacks Research

Key Points

• Zacks Research forecasts Q3 2027 EPS of ($0.01) for Novavax and Q4 2027 EPS of $0.08, while the consensus full-year estimate is a loss of ($1.46) per share.
• Novavax beat expectations in its most recent quarter (reported on Feb. 26) with $0.11 EPS versus a ($0.66) consensus and revenue of $136.4 million—up 66.6% year-over-year and well above the $90.26 million estimate.
• The stock trades near $9.62 (52-week range $5.01–$11.97) with a $1.57 billion market cap; analysts’ average rating is Hold with a $11.88 consensus price target and a mixed buy/hold/sell split, and institutional investors own about 53% of the shares.

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Analysts at Zacks Research issued their Q3 2027 earnings per share estimates for shares of Novavax in a research report issued on Thursday, March 19th. Zacks Research analyst Team expects that the biopharmaceutical company will earn ($0.01) per share for the quarter. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share. Zacks Research also issued estimates for Novavax's Q4 2027 earnings at $0.08 EPS.

Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.77. Novavax had a negative return on equity of 673.17% and a net margin of 39.19%.The business had revenue of $136.40 million during the quarter, compared to analysts' expectations of $90.26 million. During the same quarter last year, the business posted ($0.51) EPS. The business's quarterly revenue was up 66.6% compared to the same quarter last year.

NVAX has been the subject of several other research reports. Wall Street Zen upgraded shares of Novavax from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. HC Wainwright lifted their price objective on shares of Novavax from $11.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, February 27th. Weiss Ratings upgraded shares of Novavax from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, March 12th. Jefferies Financial Group reissued a "buy" rating on shares of Novavax in a report on Thursday, March 12th. Finally, BTIG Research restated a "buy" rating and issued a $19.00 price target on shares of Novavax in a research note on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $11.88.

Novavax Stock Down 1.2%

Shares of NASDAQ:NVAX opened at $9.62 on Monday. Novavax has a fifty-two week low of $5.01 and a fifty-two week high of $11.97. The firm's 50 day moving average price is $9.27 and its 200 day moving average price is $8.23. The company has a quick ratio of 2.10, a current ratio of 2.13 and a debt-to-equity ratio of 5.93. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of 3.99 and a beta of 2.54.

Institutional Trading of Novavax

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVAX. Hsbc Holdings PLC purchased a new stake in shares of Novavax during the 4th quarter worth approximately $394,000. Invesco Ltd. grew its position in shares of Novavax by 12.9% in the 4th quarter. Invesco Ltd. now owns 259,380 shares of the biopharmaceutical company's stock valued at $1,743,000 after buying an additional 29,704 shares during the last quarter. VARCOV Co. acquired a new stake in Novavax during the 4th quarter worth $263,000. Virtus Investment Advisers LLC raised its stake in Novavax by 67.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 104,019 shares of the biopharmaceutical company's stock worth $699,000 after acquiring an additional 41,866 shares in the last quarter. Finally, Oxford Asset Management LLP purchased a new stake in Novavax in the fourth quarter valued at $145,000. Institutional investors and hedge funds own 53.04% of the company's stock.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company's lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.